The Alliance for Regenerative Medicine (ARM) and UK BioIndustry Association (BIA) released a collaborative report offering an in-depth look at ATMP sector trends and metrics in the UK. The report details industry-specific statistics compiled from 56 cell therapy, gene therapy, tissue engineering, and other ATMP developers headquartered in the UK, including total financings, partnerships and other deals, clinical trial information, and clinical data events.
The UK is a cornerstone in the international life sciences community, and advanced therapy medicinal products (ATMPs) are a fast growing part of the UK economy. The UK cell and gene therapy industry employs 1,500 people; by 2035, the cell and gene therapy industry could be worth £10B and provide 18,000 jobs. This report is intended to provide an overview of the current ATMP sector landscape in the UK. The growth in this industry highlights the need for coordinated efforts to promote regulatory pathways for safe and effective products, develop and implement innovative reimbursement options, address challenges in scale-up and manufacturing, and foster international policy convergence to ensure that patients across the globe are able to access these products in a timely manner